| Literature DB >> 30382141 |
Zeinab Fereshteh1, Skye A Schmidt2, Amal A Al-Dossary1,3, Monica Accerbi2, Cecilia Arighi4, Julie Cowart4, Jia L Song1, Pamela J Green2, Kyungmin Choi5, Soonmoon Yoo5, Patricia A Martin-DeLeon6.
Abstract
Oviductosomes (OVS) are nano-sized extracellular vesicles secreted in the oviductal luminal fluid by oviductal epithelial cells and known to be involved in sperm capacitation and fertility. Although they have been shown to transfer encapsulated proteins to sperm, cargo constituents other than proteins have not been identified. Using next-generation sequencing, we demonstrate that OVS are carriers of microRNAs (miRNAs), with 272 detected throughout the estrous cycle. Of the 50 most abundant, 6 (12%) and 2 (4%) were expressed at significantly higher levels (P < 0.05) at metestrus/diestrus and proestrus/estrus. RT-qPCR showed that selected miRNAs are present in oviductal epithelial cells in significantly (P < 0.05) lower abundance than in OVS, indicating selective miRNA packaging. The majority (64%) of the top 25 OVS miRNAs are present in sperm. These miRNAs' potential target list is enriched with transcription factors, transcription regulators, and protein kinases and there are several embryonic developmentally-related genes. Importantly, OVS can deliver to sperm miRNAs, including miR-34c-5p which is essential for the first cleavage and is solely sperm-derived in the zygote. Z-stack of confocal images of sperm co-incubated with OVS loaded with labeled miRNAs showed the intracellular location of the delivered miRNAs. Interestingly, individual miRNAs were predominantly localized in specific head compartments, with miR-34c-5p being highly concentrated at the centrosome where it is known to function. These results, for the first time, demonstrate OVS' ability to contribute to the sperm's miRNA repertoire (an important role for solely sperm-derived zygotic miRNAs) and the physiological relevance of an OVS-borne miRNA that is delivered to sperm.Entities:
Mesh:
Substances:
Year: 2018 PMID: 30382141 PMCID: PMC6208369 DOI: 10.1038/s41598-018-34409-4
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Figure 1Characterization of OVS isolated from oviductal fluids (OLF). (A) Protocol for isolation of oviductosomes (OVS) from OLF using ultracentrifugation. (B) Western blot reveals the presence of CD9 (24 kDa) on OVS from proestrus (Pro-OVS), metestrus (Met-OVS), and induced estrus (IE-OVS), as well as epididymosomes (EPS) used as a positive control. Each lane contains 40 μg of protein (n = 3). (C) Negative staining and TEM of OVS show the presence of membranous vesicles of both exosomal (<100 nm) and microsomal (100 nm–1 µm) sizes. (D) Immunogold labeling (6 nm gold particles) of CD9 is shown in OVS. Gold particles on individual OVS are seen arrowed on the exterior of the membrane (D-b-d). In the absence of primary antibodies and the presence of mouse IgG, gold particles were absent (D-a), indicating the specificity of the antibody. Scale bar = 100 nm.
Figure 2Heat map with hierarchal clustering analysis of the top 50 most abundant miRNAs in purified OVS from females in Pro/Est and Met/Diest. Analysis was performed on data from two biological replicates of each sample. Yellow shading represents miRNA abundance higher than 10 transcripts per two million (10TP2M), and blue shading represents miRNA abundance between 6 and 10 TP2M. MiRNA abundance in Pro/Est and Met/Diest is consistent between samples for 88% of the miRNAs.
Figure 3Generally, miRNA expression levels in OVS are similar in Pro/Est and Met/Diest samples. (A) Eight miRNAs in the top 50 are present in different abundances in Pro/Est and Met/Diest samples. Six (12%) miRNAs are significantly more abundant in Met/Diest, and 2 (4%) miRNAs are significantly more abundant in Pro/Est, with a fold change ≥ 1.5. (*P < 0.05, **P < 0.01). (B) MiRNA abundance is correlated between Pro/Est and Met/Diest samples. Data are from 272 miRNAs with abundances of at least 2TP2M in both biological replicates of either Pro/Est or Met/Diest samples. Data shown are from Biorep 2 (R2 = 0.9655). Biorep 1 (not presented) shows a similar pattern with R2 = 0.9486.
Figure 4RT-qPCR validation of the abundance and differential expression of selected miRNAs in OVS from Pro/Est and Met/Diest. MiRNA abundance from sequencing is represented as blue columns while the relative abundance (2−ΔCt) of each miRNA assessed by RT-qPCR is represented by the red line graphs. For 3 of the 4 miRNAs (miR-143, miR-22, and let-7a), expression levels were higher in Met/Diest for both the sequencing and RT-qPCR data, and for miR-22 the differences were significant (*P < 0.05; **P < 0.04). For miR-34c, only the RT-qPCR data showed a significantly (***P < 0.003) higher expression level at Met/Diest. U6 small nuclear RNA was used as an endogenous control to normalize expression levels of miRNAs from RT-qPCR.
Figure 5Comparison of the abundance of the selected miRNAs in oviductosomes and oviductal epithelium tissue, using RT-qPCR. (A) The presence of the four selected miRNAs (miR-143, miR-34c, miR-22, let-7a) in oviductosomes (red columns) was detected in oviductal epithelial tissue (blue columns) from Pro/Est and Met/Diest females, using RT-qPCR. For both OVS and epithelial cells, expression levels were higher in Met/Diest for all miRNAs except let-7a where similar levels were seen for Pro/Est and Met/Diest in oviductal cells. With paired t-tests, abundance was significantly higher (*P < 0.05) in OVS compared to oviductal cell in Met/Diest or in both groups for all miRNAs except miR-34c-5p where the levels were similar. RT-qPCR was analyzed in duplicate using pooled samples. Expression levels were normalized using U6 small nuclear RNA as an endogenous control.
Figure 6MiRNAs levels were significantly altered in sperm after OVS-sperm interaction, following co-incubation of sperm with estrus OVS. RT-qPCR reveals that for 3 miRNAs (miR-143, miR-34c, and miR-22) sperm show significantly elevated levels, reflecting oviductosomal delivery of miRNAs after co-incubation with OVS for 30 min only. Control sperm were co-incubated in the OVS vehicle, HTF. The fourth miRNA, let-7a -5p, showed significantly reduced levels in sperm after their co-incubation with OVS for 30 min and 3 h. RT-qPCR analyses were performed in triplicate, using pooled samples. Values are the average frequencies of miRNA for each sample. Significant levels are *P < 0.05, **P < 0.01, ***P < 0.001.
Figure 7Co-incubation of sperm with OVS loaded with labeled miRNAs revealed the intracellular location of transferred miRNAs and the localization of individual miRNAs to specific sperm head sub-compartments. Following co-incubation of sperm and OVS loaded with fluorescently labeled synthetic (A) miR-143-3p, or (B) miR-34c-5p, or (C) both, sperm were visualized using confocal microscopy in an orthogonal projection composed of optical z-planes. Orthogonal projections of a sperm demonstrate a co-localization between miR-143-3p (green) and miR-34c-5p (red) with DAPI-stained nucleus (blue). Co-localization of all three (the green, the red, and the blue from the DAPI-stained nucleus) gives a white coloration (Fig. 7C). The large arrow shows the location of the centrosome with the high intensity red staining of miR- 34c-5p, while the small arrow is over the tip of the acrosome where miR-143-3p is concentrated. Sperm co-incubated with the free miR-34c-5p mixture used for loading OVS (D) or with OVS that were not loaded with miRNAs (E) were used as negative controls. The green, red, and blue lines indicate the positions at which the orthogonal surfaces intersect. Scale bars = 2 µm.
Gene targets which are regulated by 4 or more miRNAs from the top 25 miRNAs in Fig. 2.
| Targets | Count of miRNAs | miRNA list |
|---|---|---|
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
|
Functional classification for the miRNA target list using PANTHER.
| PANTHER Protein + A3:E21 Class | Count (total: 660) | Fold Enrichment | P-value | FDR |
|---|---|---|---|---|
|
| 3 | 31.88 | 5.23E-04 | 4.86E-03 |
| ▶Immunoglobulin fold transcription factor | 6 | 6.17 | 8.04E-04 | 7.17E-03 |
| ▶Transcription factor | 100 | 3.03 | 1.24E-21 | 2.65E-19 |
|
| 10 | 21.25 | 1.37E-09 | 3.25E-08 |
| ▶Cytokine receptor | 13 | 2.59 | 2.50E-03 | 2.06E-02 |
| ▶Rreceptor | 44 | 1.86 | 2.01E-04 | 2.26E-03 |
|
| 10 | 19.93 | 2.16E-09 | 4.63E-08 |
| ▶Protein kinase | 45 | 5.35 | 3.76E-18 | 2.68E-16 |
| ▶Kinase | 48 | 4.02 | 7.11E-15 | 3.80E-13 |
| ▶Transferase | 57 | 2.09 | 4.27E-07 | 8.30E-06 |
|
| 14 | 10.38 | 1.16E-09 | 3.11E-08 |
| ▶Zinc finger transcription factor | 23 | 2.41 | 2.23E-04 | 2.38E-03 |
|
| 7 | 7.97 | 7.46E-05 | 8.87E-04 |
|
| 8 | 6.71 | 6.59E-05 | 8.29E-04 |
|
| 4 | 6.38 | 5.55E-03 | 4.09E-02 |
|
| 11 | 6.15 | 6.01E-06 | 1.07E-04 |
| ▶Kinase modulator | 15 | 3.8 | 2.67E-05 | 3.80E-04 |
| ▶Enzyme modulator | 50 | 1.52 | 4.88E-03 | 3.73E-02 |
|
| 34 | 5.21 | 1.01E-13 | 4.34E-12 |
|
| 12 | 4.84 | 1.99E-05 | 3.04E-04 |
|
| 12 | 3.64 | 2.36E-04 | 2.30E-03 |
| ▶Helix-turn-helix transcription factor | 19 | 3.29 | 1.51E-05 | 2.49E-04 |
|
| 13 | 3.43 | 2.30E-04 | 2.34E-03 |
| ▶Signaling molecule | 55 | 2.65 | 5.00E-10 | 1.53E-08 |
|
| 8 | 3.11 | 6.10E-03 | 4.35E-02 |
|
| 9 | 3.02 | 4.45E-03 | 3.53E-02 |
|
| 12 | 2.94 | 1.35E-03 | 1.16E-02 |
| ▶Nucleic acid binding | 104 | 2.11 | 2.05E-12 | 7.31E-11 |
|
| 30 | 2.29 | 6.24E-05 | 8.35E-04 |
The table includes the hierarchical relations between over-represented functional classes (indicated by arrows which point to the parent term). Columns are as follows: count indicating the number of proteins from a total of 660 that map to the given functional class, the fold enrichment indicates the fold of gene–term overrepresentation associated with a given gene list compared to a background list (human set), the corresponding P-value, and the False Discovery Rate (FDR) which is the expected proportion of the observed enrichments due to random chance.
Enriched KEGG pathways obtained from the miRNA target list.
| KEGG Term | Count (total:454) | Fold Enrichment | P-value | FDR |
|---|---|---|---|---|
| hsa04151:PI3K-Akt signaling pathway | 81 | 3.57 | 3.60E-25 | 4.66E-22 |
| hsa04010:MAPK signaling pathway | 63 | 3.76 | 1.10E-20 | 1.42E-17 |
| hsa04510:Focal adhesion | 59 | 4.36 | 8.35E-23 | 1.08E-19 |
| hsa04068:FoxO signaling pathway | 52 | 5.91 | 6.02E-27 | 7.81E-24 |
| hsa04014:Ras signaling pathway | 48 | 3.23 | 4.82E-13 | 6.25E-10 |
| hsa04550:Signaling pathways regulating pluripotency of stem cells | 47 | 5.11 | 2.76E-21 | 3.58E-18 |
| hsa04060:Cytokine-cytokine receptor interaction | 43 | 2.85 | 7.02E-10 | 9.10E-07 |
| hsa04015:Rap1 signaling pathway | 42 | 3.04 | 1.33E-10 | 1.73E-07 |
| hsa04390:Hippo signaling pathway | 40 | 4.03 | 3.41E-14 | 4.43E-11 |
| hsa04722:Neurotrophin signaling pathway | 39 | 4.95 | 3.81E-17 | 4.93E-14 |
| hsa04110:Cell cycle | 38 | 4.66 | 9.85E-16 | 1.30E-12 |
| hsa04380:Osteoclast differentiation | 36 | 4.18 | 2.51E-13 | 3.26E-10 |
| hsa04919:Thyroid hormone signaling pathway | 35 | 4.67 | 1.59E-14 | 2.06E-11 |
| hsa04810:Regulation of actin cytoskeleton | 35 | 2.52 | 7.25E-07 | 9.39E-04 |
| hsa04660:T cell receptor signaling pathway | 34 | 5.02 | 3.83E-15 | 5.04E-12 |
| hsa04668:TNF signaling pathway | 33 | 4.74 | 6.66E-14 | 8.64E-11 |
| hsa04066:HIF-1 signaling pathway | 32 | 4.97 | 3.97E-14 | 5.14E-11 |
| hsa04024:cAMP signaling pathway | 32 | 2.46 | 4.23E-06 | 0.005 |
| hsa04350:TGF-beta signaling pathway | 31 | 5.62 | 2.52E-15 | 3.31E-12 |
| hsa04012:ErbB signaling pathway | 30 | 5.25 | 5.84E-14 | 7.57E-11 |
| hsa04310:Wnt signaling pathway | 30 | 3.31 | 1.34E-08 | 1.74E-05 |
| hsa04062:Chemokine signaling pathway | 29 | 2.37 | 2.62E-05 | 0.034 |
| hsa04630:Jak-STAT signaling pathway | 28 | 2.94 | 5.81E-07 | 7.53E-04 |
| hsa04921:Oxytocin signaling pathway | 28 | 2.70 | 3.31E-06 | 0.004 |
| hsa04115:p53 signaling pathway | 27 | 6.13 | 1.86E-14 | 2.42E-11 |
| hsa04914:Progesterone-mediated oocyte maturation | 26 | 4.55 | 1.30E-10 | 1.69E-07 |
| hsa04915:Estrogen signaling pathway | 26 | 4.00 | 2.62E-09 | 3.39E-06 |
| hsa04910:Insulin signaling pathway | 26 | 2.87 | 2.59E-06 | 0.003 |
| hsa04620:Toll-like receptor signaling pathway | 25 | 3.59 | 5.47E-08 | 7.10E-05 |
| hsa04931:Insulin resistance | 25 | 3.52 | 8.02E-08 | 1.04E-04 |
| hsa04071:Sphingolipid signaling pathway | 25 | 3.17 | 6.45E-07 | 8.37E-04 |
| hsa04650:Natural killer cell mediated cytotoxicity | 24 | 2.99 | 3.24E-06 | 0.004 |
| hsa04917:Prolactin signaling pathway | 23 | 4.93 | 3.44E-10 | 4.46E-07 |
| hsa04912:GnRH signaling pathway | 23 | 3.85 | 5.66E-08 | 7.33E-05 |
| hsa04114:Oocyte meiosis | 21 | 2.93 | 2.16E-05 | 0.028 |
| hsa04210:Apoptosis | 20 | 4.91 | 6.93E-09 | 8.99E-06 |
| hsa04664:Fc epsilon RI signaling pathway | 20 | 4.48 | 3.75E-08 | 4.86E-05 |
| hsa04662:B cell receptor signaling pathway | 20 | 4.41 | 4.86E-08 | 6.31E-05 |
| hsa04520:Adherens junction | 20 | 4.29 | 8.06E-08 | 1.05E-04 |
| hsa04916:Melanogenesis | 20 | 3.04 | 2.07E-05 | 0.027 |
| hsa04150:mTOR signaling pathway | 18 | 4.72 | 9.11E-08 | 1.18E-04 |
| hsa04370:VEGF signaling pathway | 17 | 4.24 | 1.16E-06 | 0.002 |
| hsa04920:Adipocytokine signaling pathway | 17 | 3.70 | 8.19E-06 | 0.011 |
| hsa04666:Fc gamma R-mediated phagocytosis | 17 | 3.08 | 8.98E-05 | 0.116 |
| hsa04512:ECM-receptor interaction | 17 | 2.97 | 1.39E-04 | 0.180 |
| hsa04064:NF-kappa B signaling pathway | 17 | 2.97 | 1.39E-04 | 0.180 |
| hsa04720:Long-term potentiation | 15 | 3.46 | 7.29E-05 | 0.094 |
| hsa04320:Dorso-ventral axis formation | 11 | 6.20 | 4.07E-06 | 0.005 |
Analysis was done using DAVID 6.8. Only non-disease pathways are shown. Columns are as follow: KEGG Term with the pathway ID and name, count indicating the number of genes from a total of 454 that map to the given pathway, the fold enrichment indicates the fold of gene–term overrepresentation associated with a given gene list compared to a background list (human set), the corresponding P-value, and the False Discovery Rate (FDR) which is the expected proportion of the observed enrichments due to random chance.
Figure 8Targets for the four selected miRNAs include those for kinases and gene regulation and appear in a number of functional classes. (A) Cytoscape representation of miRNA-target network based on data and text mining. Targets containing UniProt keyword kinase or gene regulation are colored in orange or purple, respectively. MALAT1 is a noncoding RNA and is presented in a rectangle. Targets common to more than one miRNA are indicated with a red border. (B) Classification of targets in functional classes based on PANTHER classification.
Figure 9GO (gene ontology) annotation reveals that the 4 selected miRNAs used for validation of the sequencing data are associated with a variety of reproductive processes, among other processes. The dark green color indicates the processes mapped to a common high level GO hierarchy term, whereas the light green indicates the associated processes at a more specific level.